Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured

Journal Scan / Research · October 07, 2024

Prophylactic Efficacy of Olanzapine-Based Therapy for Trastuzumab Deruxtecan–Associated Nausea and Vomiting in Patients With HER2-Positive or HER2-Low Breast Cancer

Annals of Oncology

 

Additional Info

Annals of Oncology
A randomized, double-blind, placebo-controlled phase II study of olanzapine based prophylactic antiemetic therapy for delayed and persistent nausea and vomiting in patients with HER2-positive or HER2-low breast cancer treated with trastuzumab deruxtecan: ERICA study (WJOG14320B)
Ann. Oncol 2024 Sep 05;[EPub Ahead of Print], H Sakai, J Tsurutani, Y Ozaki, H Ishiguro, K Nozawa, T Yamanaka, K Aogi, K Matsumoto, T Iwasa, M Tokiwa, M Tsuneizumi, Y Miyoshi, C Kitazawa, M Yamamoto, Y Takano, CK Imamura, Y Chiba, D Takiguchi, T Ezumi, T Takano

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading